Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Xeris Pharmaceuticals (XERS)
NASDAQ:XERS
RESEARCH TOOLSreports
Holding XERS?
Track your performance easily
XERS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.69 - $3.87
Previous CloseN/A
Volume530.95K
Average Volume (3M)1.64M
Market Cap
$477.06M
Enterprise Value$626.20M
Total Cash (Recent Filing)$32.27M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.12
Next Earnings
Mar 05, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding149,081,470
10 Day Avg. Volume1,566,388
30 Day Avg. Volume1,637,500
Standard Deviation0.25
R-Squared0.15
Alpha-0.00442
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.34
Price to Cash Flow (P/CF)-14.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.31
Enterprise Value/Revenue3.27
Enterprise Value/Gross Profit4.63
Enterprise Value/Ebitda-19.03
Forecast
1Y Price Target
$4.87Price Target Upside50.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Xeris Pharmaceuticals News
PremiumCompany Announcements
Xeris Biopharma Reports Record Third Quarter Revenue
Bulls Say, Bears Say
Bulls Say
Market ShareKeveyis for primary periodic paralysis continues to retain meaningful market share despite generic competition.
Product PerformanceRecorlev's recent commercial team expansion, combined with favorable market tailwinds in the Cushing's space, could position the product well for sustained growth in the long run.
Revenue GrowthXeris reported financials with total net product revenues of $52.9M, marking the 12th consecutive quarter of over 20% growth.
Bears Say
Financial PerformanceThe path to significant EBITDA generation remains gradual, in part due to a cost structure that seems out of proportion to the company's endocrinology/rare disease-focused commercial model.
Market RisksRisks include Gvoke competitive risk and Recorlev payer risk.
Partnerships And AgreementsAmgen terminated their XeriJect license agreement with Xeris, which might weigh on the stock incrementally.
---
Ownership Overview
8.38% Insiders
8.31% Mutual Funds
0.16% Other Institutional Investors
73.57% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
XERS FAQ
What was Xeris Pharmaceuticals’s price range in the past 12 months?
Xeris Pharmaceuticals lowest stock price was $1.69 and its highest was $3.87 in the past 12 months.
What is Xeris Pharmaceuticals’s market cap?
Xeris Pharmaceuticals’s market cap is $477.06M.
When is Xeris Pharmaceuticals’s upcoming earnings report date?
Xeris Pharmaceuticals’s upcoming earnings report date is Mar 05, 2025 which is in 48 days.
How were Xeris Pharmaceuticals’s earnings last quarter?
Xeris Pharmaceuticals released its earnings results on Nov 08, 2024. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.087 by -$0.023.
Is Xeris Pharmaceuticals overvalued?
According to Wall Street analysts Xeris Pharmaceuticals’s price is currently Undervalued.
Does Xeris Pharmaceuticals pay dividends?
Xeris Pharmaceuticals does not currently pay dividends.
What is Xeris Pharmaceuticals’s EPS estimate?
Xeris Pharmaceuticals’s EPS estimate is -0.06.
How many shares outstanding does Xeris Pharmaceuticals have?
Xeris Pharmaceuticals has 149,081,470 shares outstanding.
What happened to Xeris Pharmaceuticals’s price movement after its last earnings report?
Xeris Pharmaceuticals reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.087. Following the earnings report the stock price went up 3.274%.
Which hedge fund is a major shareholder of Xeris Pharmaceuticals?
Currently, no hedge funds are holding shares in XERS
---
Xeris Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.87 (50.31% Upside)
$4.87 (50.31% Upside)
Blogger Sentiment
Bullish
XERS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 32.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 9.8%
Last 30 Days ▲ 9.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.96%
12-Months-Change
Fundamentals
Return on Equity
222.83%
Trailing 12-Months
Asset Growth
-2.04%
Trailing 12-Months
Company Description
Xeris Pharmaceuticals
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.
---
XERS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance with record-breaking revenue growth driven by Recorlev and Gvoke, despite some challenges such as pricing pressure on Keveyis and a manufacturing write-off. The overall sentiment is positive due to the significant achievements and strong financial position.Read More>---
XERS Stock 12 Month Forecast
Average Price Target
$4.87
▲(50.31% Upside)
Technical Analysis
Ascendis Pharma
―
Eagle Pharmaceuticals
―
MannKind
―
Avadel Pharmaceuticals
―
Royalty Pharma
―
Verona Pharma
―
Best Analysts Covering XERS
1 Year
1 Year Success Rate
13/21 ratings generated profit
1 Year Average Return
+21.91%
reiterated a buy rating 7 days ago
Copying Roanna Ruiz's trades and holding each position for 1 Year would result in 61.90% of your transactions generating a profit, with an average return of +21.91% per trade.
---